Allogene Therapeutics to Present at Citi Biopharma Conference
Event summary
- Allogene Therapeutics will present at the Citi Biopharma Back to School Conference on September 9, 2026.
- The presentation is scheduled for 5:00 a.m. PT/8:00 a.m. ET.
- A webcast will be available on Allogene's website post-event for 30 days.
- Allogene focuses on developing allogeneic CAR T cell therapies for cancer and autoimmune diseases.
The big picture
Allogene's participation in the Citi Biopharma Conference underscores its efforts to engage with investors amid a competitive landscape in cell therapy. The company's focus on allogeneic CAR T therapies positions it within broader industry trends toward scalable, off-the-shelf cancer treatments. Success will hinge on demonstrating clinical efficacy and regulatory progress.
What we're watching
- Clinical Progress
- How Allogene's pipeline advancements will impact investor sentiment and valuation.
- Regulatory Pathways
- Whether the company can navigate the regulatory challenges associated with novel cell therapies.
- Market Positioning
- The pace at which Allogene can differentiate itself in the competitive CAR T cell therapy space.
Related topics